© Copyright 2004-2015 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

 In the News:

Artificial Intelligence optimizes discovery of future drugs

Read press release (pdf)

Direct access to all pages:

Site map

Several newspapers
published detailed reports
about PharmaInformatic,
click here to read.

  Get In Contact
    LinkedIn   Twitter

PharmaInformatic was founded in 2004 and provides ADME Knowledge Bases and predictive tools (Expert Systems) to improve drug discovery and development. The company is based in Emden, Germany.

About two-thirds of drug-candidates fail in clinical trials due to lack of efficacy (insufficient drug-uptake).  Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans (Oral Bioavailability) prior to clinical trials.

Recent collaborations:   Lead optimisation & drug-candidate selection
Research collaboration with AVIVIA BV
evaluated and prioritised prodrugs for the treatment of cancer based on estimated oral bioavailability in humans. Selected candidate now in human clinical trials (more).

UNIZYME Laboratories A/S and PharmaInformatic have entered into a collaboration for the development of new therapeutic agents for the treatment of inflammatory and autoimmune diseases (more).

BRIDGE BIORESEARCH PLC and PharmaInformatic have signed a collaboration agreement. Prediction of oral bioavailability of drug candidates for the treatment of type 2 diabetes by using IMPACT-F (more).


IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F accelerates drug discovery and development: It calculates oral bioavailability of future drugs in humans. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. Read our current research results on bioavailability of drugs.

Computational models such as IMPACT-F replace animal trials: they require no experimental effort and results are almost immediately available. Since they are significantly more reliable than animal models, they increase the prospects of successful clinical trials in humans.

PACT-F:  Largest knowledge base on bioavailability of drugs worldwide

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs. The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database (more).

PACT-F is now the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals, see content of PACT-F.

Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail.